Project/Area Number |
23592146
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cerebral neurosurgery
|
Research Institution | Osaka Medical College |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
FURUSE Motomasa 大阪医科大学, 医学部, 講師 (70340560)
IKEDA Naokado 大阪医科大学, 医学部, 非常勤講師 (50434775)
MATSUSHITA Yoko 大阪医科大学, 医学部, 助教 (70512094)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 脳腫瘍学 / 悪性神経膠腫 / 放射線治療 / ホウ素化合物 / 中性子捕捉療法 / 合成アミノ酸 / ドラッグデリバリーシステム |
Research Abstract |
Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive Boron-10 is irradiated with low energy thermal neutrons to produce alpha- particles inside one cell level. The L-amino acid transport system in tumor cells is enhanced compared with normal cells. We designed, synthesized and tested boron carrying unnatural amino-acid, ACBC-BSH, as boron drug for BNCT. Curative effect of ACBC-BSH groups was approximately equal to BPA. The reason is that we think that extracellular accumulations of ACBC-BSH indicating that the seemingly high tumor boron concentrations did not represent the true tumor cellular uptake. And we did not compete for the curative effect by using ACBC-BSH together in BPA and accepted meaningful duration of survival time. Difference in drug distribution at the cell level was regarded as the cause. This study suggested the possibility that ACBC-BSH became the drug to add curative effect to.
|